Advertisement
UK markets closed
  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     
  • HANG SENG

    17,201.27
    +372.34 (+2.21%)
     
  • CRUDE OIL

    82.65
    -0.71 (-0.85%)
     
  • GOLD FUTURES

    2,339.70
    -2.40 (-0.10%)
     
  • DOW

    38,362.09
    -141.60 (-0.37%)
     
  • Bitcoin GBP

    51,968.82
    -1,674.67 (-3.12%)
     
  • CMC Crypto 200

    1,398.28
    -25.82 (-1.81%)
     
  • NASDAQ Composite

    15,669.42
    -27.22 (-0.17%)
     
  • UK FTSE All Share

    4,374.06
    -4.69 (-0.11%)
     

Kering - Information regarding the arrangements for taking part in the Combined General Meeting of April 27, 2023 and conditions for obtaining or consulting the documents prepared for the meeting

PRESS RELEASE

April 14, 2023

INFORMATION REGARDING THE ARRANGEMENTS FOR TAKING PART IN THE COMBINED GENERAL MEETING OF APRIL 27, 2023 
AND CONDITIONS FOR OBTAINING OR CONSULTING THE DOCUMENTS PREPARED FOR THE MEETING

Kering shareholders are invited to attend the Company’s Combined General Meeting to be held at 3 p.m. on Thursday, April 27, 2023 (Paris time) at Kering’s headquarters – 40 rue de Sèvres, 75007 Paris, France.

The General Meeting will be held in the physical presence of the shareholders and will also be broadcast live and available for replay on the Company's website1:
www.kering.com/en (Finance/Shareholders Information/Annual General Meeting section).

ADVERTISEMENT

The Notice of Meeting, including the agenda, the proposed resolutions submitted to shareholders by the Board of Directors and a description of the main options available to shareholders in terms of taking part in and voting at the General Meeting and exercising their rights, was published on March 22, 2023, in the Bulletin des Annonces Légales Obligatoires (BALO – French bulletin of legal notices).

The convening notice was published in the BALO and the legal gazette (online news service) Les Affiches Parisiennes on April 7, 2023.

Shareholders are entitled to submit written questions before the General Meeting (preferably by email to AG2023proxy@kering.com) at least four business days before the General Meeting, i.e., on Friday, April 21, 2023 at the latest, and must be accompanied by a share ownership certificate.

In compliance with provisions of the French Commercial Code (Code de commerce), the documents relating to the General Meeting (including, in particular, the 2022 Universal Registration Document and the proxy/postal voting form) are available on the Company’s website at www.kering.com/en/ (Finance/Shareholders information/Annual General Meeting section).

The documents relating to the General Meeting are made available or communicated to the shareholders since April 7, 2023 and are available in the section dedicated to the General Meeting on the Company's website www.kering.com/en, in accordance with the legal and regulatory conditions in force.

About Kering

A global Luxury group, Kering manages the development of a series of renowned Houses in Fashion, Leather Goods and Jewelry: Gucci, Saint Laurent, Bottega Veneta, Balenciaga, Alexander McQueen, Brioni, Boucheron, Pomellato, DoDo, Qeelin, as well as Kering Eyewear. By placing creativity at the heart of its strategy, Kering enables its Houses to set new limits in terms of their creative expression while crafting tomorrow’s Luxury in a sustainable and responsible way. We capture these beliefs in our signature: “Empowering Imagination”. In 2022, Kering had over 47,000 employees and revenue of €20.4 billion.

Contacts

Press
Emilie Gargatte                        +33 (0)1 45 64 61 20                emilie.gargatte@kering.com
Marie de Montreynaud                +33 (0)1 45 64 62 53                marie.demontreynaud@kering.com 

Analysts/investors
Claire Roblet                         +33 (0)1 45 64 61 49                claire.roblet@kering.com
Julien Brosillon                         +33 (0)1 45 64 62 30                julien.brosillon@kering.com

Follow us on:


1 Unless technical reasons make this broadcast impossible or seriously disrupt it.

Attachment